Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML)

Chemotherapy has been the standard of treatment for acute myeloid leukemia (AML). With the emergence of new therapies for AML like gemtuzumab-ozogamicin and FLT3 inhibitors, such as sorafenib, midostaurin, and gilteritinib, the optimal dose of chemotherapy and safety profile in different age groups...

Descripción completa

Detalles Bibliográficos
Autores principales: Vegunta, Rathnamitreyee, Harel, Ronen, Steinberg, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308398/
https://www.ncbi.nlm.nih.gov/pubmed/35898381
http://dx.doi.org/10.7759/cureus.26240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308398/
https://www.ncbi.nlm.nih.gov/pubmed/35898381
http://dx.doi.org/10.7759/cureus.26240

Ejemplares similares